Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
abandonment, Actemra, alleviate, amelioration, Amgen, ANA, andin, anti, antinuclear, APA, approximetaly, artificial, azathioprine, bid, Biogen, Bulletin, cevilemine, cevimeline, cholinergic, classic, cyclosporine, dry, ECL, Evoxac, exocrine, extraglandular, female, Fopundation, fromin, FVOCI, gastrointestinal, gland, glandular, HCW, hundred, hydroxychloroquine, Hypergammaglobulinemia, Immunomodulary, immunomodulatory, incubated, incubation, infiltration, interstitial, isolated, Kingdom, lacrimal, liver, lung, lymphocytic, mofetil, mononuclear, mouth, mRNA, myalgia, mycophenolate, neurologic, ocular, OTC, OTCQX, ourADSscould, page, parotid, penny, pilocarpine, precentage, presence, provisional, pSS, pulmonary, quotation, recieved, regained, relief, Renshaw, RF, Rituxan, rituximab, Roche, Rodman, RSLV, Salagen, salivary, sicca, Sjogren, SPA, SS, SSA, SSB, stimulation, Strasbourg, suitable, symptomatic, symptomatically, syndrome, thourgh, undertaken, unsolicited, usage, vasculitic, volatilityand, Wainwright, Wehave, xerophthalmia, xerostomia
Removed:
accumulation, acute, African, allogeneic, begun, binding, bleeding, blended, bone, bortezomib, bringing, broadly, buyer, capitalized, carfilzomib, channel, chemotherapy, clonal, cloning, collecting, combined, compartment, computed, conclusion, conferred, constructive, continuance, culture, cumulatively, decade, Delaware, depending, derecognized, devastating, deviation, differentiation, disabled, dispersion, distributor, domiciled, doubtful, enacted, encourage, Enterprise, erythroid, Erythropoetin, examined, experimental, extend, finite, forfeiture, fulltime, glycoprotein, gradual, gradually, haematopoietic, hormone, immunologically, intragroup, IRB, Knesset, led, lenalidomide, lineage, lived, location, malignancy, mammalian, managerial, marrow, master, men, merchandise, nausea, observation, partly, pathological, periodically, phased, plant, point, pomalidomide, Pomalyst, poor, progenitor, prognostic, progressive, proliferation, promoting, receptor, reclassified, recurrent, red, regulator, reissued, relapsed, remission, revlimid, seller, selling, settle, sheet, Society, solid, sourced, stem, substantively, supplementary, surface, susceptibility, systematically, today, transplantation, twenty, uncollectible, updated, upkeep, Velcade, viability, vital, vomiting, warranty
Filing tables
Filing exhibits
XTLB similar filings
Filing view
External links
Exhibit 23.2
LETTER OF CONSENT
We hereby consent to the reference to our report, as detailed below, in the annual report on form 20-F of XTL Biopharmaceuticals Ltd. (hereinafter: “XTL”) for the year ending December 31, 2016, dated March 30, 2017.
· | Impairment examination study of XTL’s intangible asset, dated March 31, 2016 |
/s/ BDO Ziv Haft Consulting and Management Ltd. |
Tel Aviv, Israel |
March 30, 2017 |